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ABSTRACT 
Leukotrienes are potent immune-modulatory compounds involved in the inflammatory 
response. 5-Lipoxygenase (5-LOX) is the enzyme that catalyzes the production of Leukotriene 
A4 (LTA4), which is further metabolized to pro- and anti-inflammatory compounds derived 
from the substrate Arachidonic Acid (AA), a polyunsaturated fatty acid. The crystal structure 
of a stabilized form of 5-LOX has been recently reported (Gilbert, Bartlett et al. 2011). 
However, the structure does not reveal the mode of substrate entry or recognition.  
The first step in the enzymatic reaction involves the removal of a hydrogen from the 
central carbon of a pentadiene present in the substrate. It is not known how 5-LOX 
distinguishes among three such chemically equivalent pentadienes in AA to produce only 5-S-
HPETE, which is subsequently transformed to LTA4. The crystal structure suggests a 
somewhat crescent shaped active site lined with invariant Leucines and Isoleucines, with no 
clear access port visible for substrate entry. 
A series of site-directed mutants were produced and the activities of these mutants 
evaluated. Product analyses of these mutants with AA and substrate analogs suggest entry of 
the substrate by the opening of the so-called Phenylalanine (F)-Tyrosine(Y) ‘cork’. The data is 
also consistent with the orientation of AA as carboxyl innermost, as predicted from the 
stereochemistry of the product and mechanistic models of lipoxygenase function.
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CHAPTER 1. INTRODUCTION 
1.1 The Lipoxygenase Enzyme Family: A Structural Overview 
Lipoxygenases (LOXs) are a class of enzymes that produce hydroperoxy fatty acid 
precursors by addition of a molecule of oxygen onto a polyunsaturated fatty acid substrate 
containing at least one cis,cis-1,4-pentadiene moiety (Brash 1999, Andreou and Feussner 
2009). Lipoxygenases have a widespread presence in the living world, being found in animal, 
plants, fungi and even bacteria (Joo and Oh 2012). Apart from that, multiple isoforms of 
lipoxygenase are generally present in a particular species having functional differences 
between them. For example, more than twenty different LOX genes have been recognized in 
the rice genome, seven different ones are seen in the murine genome and the human genome 
contains six functional LOX genes (Ivanov, Heydeck et al. 2010). The hydroperoxy fatty acid 
products generated by LOX action are further metabolized into bioactive compounds with 
diverse roles such as leukotrienes and lipoxins in higher animals (Haeggstrom and Funk 2011), 
jasmonic acids in plants (Mosblech, Feussner et al. 2009), and lactones in microorganisms 
(Huang and Schwab 2011). 
When we look at the basic fatty acid oxygenation by LOXs, it fundamentally consists 
of four sterically controlled reaction steps mediated by a non heme iron moiety: hydrogen 
abstraction, radical rearrangement, oxygen insertion and peroxy radical reduction (Ivanov, 
Heydeck et al. 2010). (Figure 1) (Next page) 
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Figure 1: General mechanism of lipoxygenase reaction. The reaction is initiated by stereo 
selective hydrogen abstraction at the central carbon (Cn) of a cis, cis-1, 4-pentadiene; the 
resulting radical can migrate over the neighboring double bond at either Cn+2 or Cn-2 and react 
with molecular oxygen to form a peroxy radical. The oxidation of the active site iron provides 
an electron for the formation of a peroxyanion, which is then protonated into a hydroperoxide. 
The hydrogen abstraction and insertion of oxygen are anatarafarcial in nature i.e., they occur 
on opposite sides of the substrate. 
3 
Structurally, all lipoxygenases, irrespective of their origins, share a predominantly α-
helical catalytic domain. The main feature of this domain is the highly conserved ‘catalytic 
core’ comprised of about 17 helices encompassing the catalytic iron within. The catalytic site is 
defined by four core helices, with helices α7 and α14 on one side of the iron moiety and the α8 
helix (‘arched helix’) and the penultimate helix on the other side (Newcomer and Brash 2015). 
The iron coordination sphere exhibits pseudo octahedral geometry with several invariant 
histidine side chains from the core helices α7 and α14 as well as the main chain carboxyl of the 
C-terminal, invariant Ile, acting as the ligands (Gaffney 1996). The arched helix, so called due 
to its distinctive curvature found in all solved LOX structures, helps shield a U-shaped catalytic 
cavity from the outer solution state (Minor 1996). 
In addition to the above, the animal and plant enzyme also have an additional β-barrel 
domain at the N-terminus, known as the Polycystin-1, Lipoxygenase, Alpha-Toxin (PLAT) 
domain. Even though the PLAT domains display a high degree of structural conservation, 
unlike the catalytic domain, they show much less sequence conservation. This domain of LOXs 
is involved in membrane binding aided by Ca2+ (Hammarberg, Provost et al. 2000, Kulkarni, 
Das et al. 2002). This domain might also have a regulatory role in catalysis even though it is 
not vital for enzyme action (Ivanov, Di Venere et al. 2011). (Figure 2) (Next page). As the 
figures suggest it is also notable that the PLAT domain in plants is larger than animals. Also, 
the absence of a PLAT domain in bacterial LOXs is consistent with the fact that they are 
secreted as soluble enzymes (Hansen, Garreta et al. 2013). 
. 
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Figure 2: Lipoxygenase Structure Comparison. Lipoxygenase structure examples from Bacteria 
(cyan), Plant (green) and Animal (magenta) are shown. The additional PLAT domains in Plant 
and Animal specimens are indicated by blue boxed regions. 
 
1.2 Mammalian Lipoxygenases and their Biological importance  
I will now focus on the mammalian LOX isoforms in general and 5-LOX in particular 
for their relevance to this body of work. The physiological importance of LOXs in the 
mammalian systems is highlighted by the fact that several isoforms have been discovered with 
diverse roles in maintenance of proper cellular function. Table 1 lists a summary of LOX 
isoforms present in human and their murine counterparts. summarizes and assigns names of the 
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genes to the different isozymes for the ease of identification of their respective activities (small 
letters for mouse and capital letters for human genes) (Kuhn, Banthiya et al. 2015). 
Table 1. Human ALOX genes and major expression sites of the corresponding LOX-isoforms. 
Human 
gene 
Former 
name 
Mouse 
gene 
Former 
name 
Major 
expression 
References 
ALOX5 5-LOX alox5 alox5 Leukocytes, 
macrophages, 
dendritic cells 
(Funk, Hoshiko et al. 
1989, Ghosh 2003, 
Faronato, Muzzonigro 
et al. 2007, Wasilewicz, 
Kolodziej et al. 2010) 
ALOX12 pl12-
LOXb 
alox12 pl12-
LOX 
Thrombocytes, 
skin 
(Funk, Furci et al. 
1990, Johnson, Brass et 
al. 1998, Virmani, 
Johnson et al. 2001) 
ALOX12B 12R-
LOX 
alox12b 12R-
LOX 
Skin (Boeglin, Kim et al. 
1998, Meruvu, Walther 
et al. 2005) 
ALOX15 12/15-
LOX 
alox15 Lc12-
LOXa 
Eosinophils, 
bronchial 
epithelium 
(Sigal, Grunberger et 
al. 1988, Sigal, Sloane 
et al. 1993) 
ALOX15B 15-
LOX2 
alox15b 8-LOX Hair roots, 
skin, prostate 
(Brash, Boeglin et al. 
1997, Jisaka, Kim et al. 
1997) 
ALOXE3 eLOX3 aloxe3 eLOX3 Skin (Kinzig, Heidt et al. 
1999, Yu, Schneider et 
al. 2006, Krieg and 
Fuerstenberger 2014) 
Pseudogene alox12e elox12 Skin (Funk, Chen et al. 
2002) 
a: lc — leukocyte-type. b: pl — platelet-type. 
Now, it is well known that LOXs are involved in modulating cellular activity by the 
formation of lipid mediators using free polyenoic fatty acid substrates. The primary products of 
the LOX pathway are subsequently converted to a large array of bioactive lipid mediators, 
which include leukotrienes (Savari, Vinnakota et al. 2014), lipoxins (Romano 2010), 
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hepoxilins (Pace-Asciak 2009), eoxins (Sachs-Olsen, Sanak et al. 2010), resolvins (Yoo, Lim 
et al. 2013), protectins (Serhan and Petasis 2011) and others originating from AA, EPA and 
DHA. These signaling molecules have been seen in both the pro and anti- inflammatory 
responses. Apart from this, LOXs might affect cellular metabolism by other ways as well 
(Figure 3). 
Firstly, several LOX isoforms have been shown to be capable of oxidizing complex ester 
lipids (Belkner, Wiesner et al. 1991) and even lipid-protein assemblies such as cell membranes 
and lipoproteins (Schewe, Rapoport et al. 1986). The introduction of a hydrophilic peroxide 
group into the hydrophobic tail of a fatty acid changes the physiological properties of the ester 
lipids. Such oxidized lipids can come together to form “hydrophilic pores” within the lipid 
bilayer of a cell membrane. This impairs barrier function of the membrane which, in turn, may 
lead to cellular dysfunction(van Leyen, Duvoisin et al. 1998). This particular ability can also 
implicate LOXs in having at least a partial role in erythropoiesis (Koury, Sawyer et al. 2002), 
epidermal differentiation(Epp, Fuerstenberger et al. 2007, Kypriotou, Huber et al. 2012) and 
atherogenesis (Zhao and Funk 2004, Poeckel and Funk 2010). 
Another way by which LOXs exert their activity is by forming lipid peroxides, LOXs can 
modify the cellular redox state. The cellular redox equilibrium is an important regulator of gene 
expression (Forman, Ursini et al. 2014) and such intracellular LOX’s activity has also being 
associated with cell proliferation and carcinogenesis (Nie, Hillman et al. 1998, Kelavkar, Nixon 
et al. 2001, DuBois 2003). Although the exact nature of their role remains unclear, the 
expression of LOXs in humans is highly affected in prostrate (Matsuyama and Yoshimura 2008) 
and colorectal (Cathcart, Lysaght et al. 2011) carcinomas. 
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Figure 3. Biological function of lipoxygenases. Lipoxygenases may exhibit their biological 
functionality via three different mechanistic scenarios: i) Formation of bioactive lipid 
mediators, ii) structural modification of complex lipid–protein assemblies and iii) modification 
of the cellular redox homeostasis, which alters the gene expression pattern(Kuhn, Banthiya et 
al. 2015). 
 
1.3 Leukotrienes: Pathophysiological Importance 
Leukotrienes are extremely pathologically significant, particularly due to their role in 
inflammation. As the name implies, leukotrienes are predominantly produced by leukocytes 
due to their high level of 5-LOX and FLAP expression. However, different cell types have 
different levels of actual LTs produced (Peters-Golden and Henderson 2007). Neutrophils 
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produce only LTB4 and eosinophils, mast cells, and basophils produce mostly cysLTs. In 
contrast, macrophages and dendritic cells are capable of making both LTB4 and cysLTs. 
Certain non-leukocyte cell types in humans, such as bronchial fibroblasts and epithelial cells 
are capable of producing minor amounts of LTs owing to low level expression of 5-LOX and 
FLAP (James, Penrose et al. 2006, Jame, Lackie et al. 2007). Overall tissue biosynthesis of 
LTs is also affected by non-leukocyte cells due to their expression of distal LTA4 -
metabolizing enzymes LTA4H and LTC4S. This enables them to produce LTs even in the 
absence of 5-LOX/FLAP through “transcellular biosynthesis” (Fabre, Goulet et al. 2002). This 
process involves the transfer of LTA4 from a donor cell (typically a leukocyte such as a 
neutrophil) to a recipient cell (typically a non-leukocyte such as an endothelial cell), which can 
convert it to, for example, LTC4  (Okunishi and Peters-Golden 2011). 
The leukotriene biosynthesis cascade begins with the synthesis of Leukotriene A4 
(LTA4) by oxidation of arachidonic acid (AA) by 5-Lipoxygenase through a two-step reaction 
(Rådmark, Werz et al. 2007). In the first step a hydrogen atom is abstracted from the C7 of 
AA, followed by the addition of molecular oxygen, to generate 5-HpETE (5-
hydroperoxyeicosatetraenoic acid). The second step involves removal of a hydrogen atom from 
C-10, resulting in formation of the allylic epoxide LTA4 followed by the release of the product 
from the enzyme. LTA4 is a substrate for both LTA4-H (LTA4 hydrolase) and LTC4-S 
[LTC4 (leukotriene C4) synthase].  LTA4-H generates LTB4 [leukotriene B4, 5(S), 12(R)-
dihydroxy-6, 8, 10, 14-(Z, E, E, Z)-eicosatetraenoic acid] by the stereo specific addition of 
water to C-12. On the other hand, LTC4-S forms the product LTC4 [5(S)-hydroxy-6(R)-S-
glutathyionyl-7, 9, 11, 14(E, E, Z, Z)-eicosatetraenoic acid], by addition of a glutathione at C-6 
(Murphy and Gijon 2007). LTC4 is exported out of the cell where it can be processed by γ-
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glutamyl transpeptidase to LTD4 and finally to LTE4 by dipeptidase hydrolysis. These three 
LTs are also known as cysteinyl LTs owing to the fact that they all have a cysteine moiety 
attached to the C-6 via thiol linkage. (Figure 4). 
 
Figure 4. Leukotriene Synthesis Cascade. AA is converted to LTA4 by the action of 5-LOX. 
This is then converted to LTB4
 by the enzyme LTA4 Hydrolase. LTA4 is also a precursor to 
cysteinyl Leukotriene (cysLT), LTC4 through addition of glutathione by the enzyme LTC4 
Synthase. LTC4 can be further metabolized into other cystienyl LTs, LTD4 (by γ-glutamyl 
transpeptidase) and subsequently into LTE4 (by Dipeptidase). 
 
LTs are extensive studied mediators of inflammation (Haeggstrom and Funk 2011). 
LTs act by binding to specific G protein-coupled receptors that are located on the outer 
plasma membrane of structural and inflammatory cells (Peters-Golden and Henderson 2007). 
The different LTs can have distinct cellular targets and activities such as smooth muscle cell 
contraction by cysLTs and neutrophil chemotaxis (Palmblad, Malmsten et al. 1981) by LTB4. 
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Specifically, LTB4 is a potent mediator of innate immune response (Soares, Mason et al. 
2013). It can induce intracellular signaling cascades leading to activation of inflammatory 
cells by binding to cell surface receptors BLT1 and BLT2 (Hicks, Monkarsh et al. 2007, 
Back, Powell et al. 2014). LTB4 also induces cell aggregation, increases vascular 
permeability (Smith 1981) and aids the adherence of neutrophils to the vascular walls 
(Afonso, Janka-Junttila et al. 2012). 
The cysLTs are involved in anaphylaxis and are important effectors of allergic diseases. 
They may play a role in pulmonary distress due to powerful broncho-constrictor properties 
(Dahlen, Hedqvist et al. 1980), ability to cause bronchial edema (Dahlen, Bjork et al. 1981) 
and increasing mucus secretions (Peatfield, Piper et al. 1982, Kaliner, Shelhamer et al. 1986). 
They have also been implicated in bronchial asthma (Singh, Tandon et al. 2013), rhinitis 
(Cobanoglu, Toskala et al. 2013) and allergic eye disease (Gane and Buckley 2013). 
1.4 Human 5- Lipoxygenase - relationship between structure and function: 
The human 5-lipoxygenase is a 673 aa, Ca2+ activated (Hammarberg, Provost et al. 
2000), membrane binding enzyme, which is aided by the proteins FLAP (5-LOX Activation 
Protein) (Abramovitz, Wong et al. 1993) and CLP (coactosin like protein) (Rakonjac, Fischer 
et al. 2006). However, the wild type 5-LOX posed considerable challenge for successful 
crystallization. To alleviate this issue a ‘Stable 5-LOX’ was engineered by removal of 
destabilizing effects of candidate membrane and Ca2+ binding amino acids via mutations 
(Gilbert, Bartlett et al. 2011). 
At first glance the structure of human 5-LOX exhibits all classical structural features 
seen in mammalian LOXs. The residues 1-112 form the primarily beta sheeted N-terminal 
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regulatory domain(Allard and Brock 2005) and the residues 125-673 form the much larger C-
terminal catalytic domain. As expected, this domain houses the catalytic site with a catalytic 
iron forming the center of the catalytic action. The active site cavity appears to somewhat 
follow the current LOX structural consensus (Newcomer and Brash 2015) by having a partial 
U shaped cavity lined with highly conserved Leu and Ile residues. 
 However, on close inspection, this structure presents a unique catalytic cavity. The 
catalytic center appears to be completely shielded from outer solvent state with no obvious 
substrate access site. The helix α2 is much shorter compared to what is seen in others with the 
side chains of residues Phe 177 and Tyr 181 positioned to impede access into the catalytic 
cavity (Figure 5). Exploring the possible role of this so called F-Y plug in substrate access and 
enzyme activity has been a major focus of my research presented below. The putative actions 
of the plug in overall enzyme activity have been referred as ‘corking’ and ‘decorking’ 
henceforth. 
The catalytic Fe in this enzyme is held into place by coordination with side chains of 
three conserved His residues (numbered 367, 372 and 550) and the main chain carboxyl group of 
the C-terminal Ile 673(Gilbert, Bartlett et al. 2011). It may be also aided in this by the residue 
Asn 554 (Figure 6), which is not close enough to be present in the actual coordination sphere. As 
far as the reaction mechanism is concerned this catalytic Fe acts as both an electron donor and 
acceptor during the course of the reaction (Figure 7). 
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Figure 5. Comparison of α2 helix of 5-LOX with other LOXs. (A) The helix in 5-LOX (blue) is 
much shorter as compared to the corresponding helices in 12-LOX (yellow) and 15-LOX 
(green). The ‘F-Y plug’ is shown in context to the catalytic Fe. (B) The position of the FY plug 
amino acid side chains (purple sticks) and their region of influence (purple mesh) is shown with 
respect to 5-LOX active site contour (blue). 
 
 
Figure 6. Coordination of Catalytic Fe in 5-LOX. The Fe moiety (rust) is held in place by 
coordination bond formation with amino acid residues (green stick representation) in the 
catalytic center of 5-LOX. 
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Figure 7. The various states of catalytic Fe during 5-LOX action. The inactive enzyme (red 
boxed form) is activated (blue boxed form) by the lipid hydroperoxide (LOOH). The reduction 
state of  Fe changes several times during the reaction ( indicated by the green arrows)[Adapted 
from (Murphy and Gijon 2007)]. 
 As mentioned earlier, abnormal activity of  5-LOX  has been implicated in in several 
disorders related to allergy and inflammation, such as asthma, rheumatoid arthritis, psoriasis etc. 
(Henderson 1994). Products of 5-LOX pathway have also been associated with carcinogenesis 
(Sethi, Shanmugam et al. 2012) and atherosclerosis in Humans (Jawien and Korbut 2010). 
Needless to say these pathological effects of 5-LOX make it an attractive candidate for drug 
targeting. So far the only drug specifically targeting 5-LOX that has made to commercial 
distribution is Zileuton (Carter, Young et al. 1991). This leaves the field wide open for the 
development of more selective and effective drugs against 5-LOX.  
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As seen from the available literature, 5-LOX has far reaching effects in the coordination 
of physiological processes in a living individual. The various effects of 5-LOX activity in the 
Human system makes it a promising drug target. Even though the structure of a stabilized form 
of this enzyme is available (Gilbert, Bartlett et al. 2011), the distinctive active site cavity and its 
apparent lack of an obvious entry point for the substrate gives us an incomplete picture. My 
research is aimed at enhancing our understanding of how this particular enzyme works and how 
it activity is controlled. This will not only help to further our knowledge about this important 
enzyme but will also aid in design and development of suitable pharmacological targeting 
candidates 
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CHAPTER 2. IDENTIFICATION OF THE SUBSTRATE ACCESS 
PORTAL OF 5-LIPOXYGENASE 
 
2.1 Overview 
The overproduction of inflammatory lipid mediators derived from arachidonic acid 
contributes to asthma and cardiovascular diseases, among other pathologies.  Consequently, 
the enzyme that initiates the synthesis of pro-inflammatory leukotrienes, 5-lipoxygenase, is a 
target for drug design. The crystal structure of 5-LOX revealed a fully encapsulated active 
site and how the substrate gains access is unknown (Figure 8).  
 
Figure 8. Possible substrate entry points in 5-LOX. The blue contour rendering of the 5-LOX 
active site indicates a completely enclosed active site. The possible sites for the entry of  AA 
are indicated by green arrows and the likely amino acid side chains (purple) that might be 
involved in those sites are also indicated. Removal of the plug requires the movement of both 
main chains and side chains of the amino acids while for ‘portal’ entry only rotamer shift of 
the Trp 147 side chain is required. 
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We then asked whether a structural motif, aromatic “corking” amino acids,  present in 
5-LOX but absent in other mammalian lipoxygenases, might reposition to allow substrate 
access. Our results indicate that reduction of cork volume facilitates access to the active site. 
However, if the site is obstructed, enzyme activity is severely compromised. Our results 
support a model in which the “corking” amino acids shield the active site in the absence of 
substrate, and help position the substrate for catalysis. 
2.1 Introduction 
The enzyme 5-lipoxygenase (5-LOX) initiates the biosynthesis of the eicosanoid lipid 
mediators known as leukotrienes (LT). Together with 5-Lipoxygenase-Activating Protein 
(FLAP), localized to the nuclear membrane, 5-LOX transforms arachidonic acid (AA) to 
leukotriene (LT) A4  in a two-step reaction that proceeds via a hydroperoxy intermediate 
(Haeggstrom and Funk 2011, Radmark, Werz et al. 2014). Downstream metabolites of LTA4 
are potent signaling molecules involved in diverse processes, some of which are mediated by 
G-Protein coupled receptors. For example, LTD4 and LTC4 induce bronchoconstriction upon 
binding to their cognate G-Protein Coupled Receptors in smooth muscle cells, while LTB4 is 
a potent leukocyte chemoattractant (Funk 2001). Due to its role in the production of 
inflammatory lipid mediators, 5-LOX is a target for the development of therapeutics for  
conditions as diverse as asthma, cardiovascular disease, (Pergola and Werz 2010, Steinhilber 
and Hofmann 2014) pancreatic cancer (Sarveswaran, Chakraborty et al. 2015) and  traumatic 
brain injury (Corser-Jensen, Goodell et al. 2014). 
Lipoxygenases are non-heme iron dioxygenases that catalyze the peroxidation of 
polyunsaturated fatty acids (Brash 1999, Kuhn and Thiele 1999). Humans express six 
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lipoxygenases (Funk, Chen et al. 2002), and each is named according to the site of 
peroxidation of AA. Thus, 5-LOX produces the intermediate 5-hydroperoxyeicosatetraenoic 
acids (5-HpETE), whereas, for example, a 15-LOX produces 15-HpETE. Thus while animal 
LOXs metabolize a common substrate, they differ in product specificities.  
The product generated is both stereo-specific and regio-specific, as either a specific 
R- or S- isomer is produced even though the substrate of choice AA has 3 possible sites for 
hydrogen abstraction and thus can theoretically generate 12 possible products (Figure 9). 
 
Figure 9. Arachidonic Acid as a substrate. The red blue and green colored regions indicate 
the three chemically equivalent carbons and their associated hydrogens available for 
abstraction. The possible products with their sterio and region identities are color coordinated  
Both the 5- and 15-enzymes produce the S-isomers of their respective products. The 
stereo-chemistries of these two products are consistent with two distinct modes of substrate 
binding (Schneider, Pratt et al. 2007) (Figure 10) corresponding to head-first (carboxyl) or 
tail-first (hydrocarbon) entry into the active  site (Egmond, Vliegenthart et al. 1972, Coffa, 
Imber et al. 2005).  
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One of three AA pentadienes must be positioned with its methylene carbon accessible 
to the catalytic machinery for H abstraction, and H abstraction generates a free radical that is 
accessed by O2 from the opposite face of the AA. The stereo-chemistry of the product is a 
consequence of this antarafacial relationship between the catalytic iron and the O2 access 
channel/pocket.  
 
Figure 10. LOX product stereo-chemistries are consistent with one of two orientations of AA is 
the active site.  (a) Contour of the active site (shaded region) of 15-LOX-2 (pink, 4NRE) as 
defined by a competitive inhibitor in green.  The α2 helix of 5-LOX in blue cartoon rendering 
and stick rendering of the F-Y plug is superimposed on the 15-LOX-2. (b) The equivalent 
rendering of 5-LOX (blue, 3O8Y). (c)  For cavities of equal depth, inverse positioning of the 
substrate generates the 15-S- “tail-first” product or the 5-S “head-first” product. 
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Several LOX structures are available and combine to provide details of a consensus 
active site (Newcomer and Brash 2015), but the 5-LOX isoform differs significantly from 15-
LOX-1 (Gillmor, Villasenor et al. 1997, Choi, Chon et al. 2008), 15-LOX-2 (Kobe, Neau et al. 
2014), 12-LOX (Xu, Mueser et al. 2012)  and 8R-LOX (Oldham, Brash et al. 2005, Neau, 
Bender et al. 2014)  in three important ways:    (1) The HPETE produced by 5-LOX is an 
intermediate; a second reaction in the same 5-LOX active site converts the intermediate to 
LTA4. (However, it should be noted that in vitro 15-LOX-1 can also utilize 15-HPETE as a 
substrate and generate a product analogous to LTA4 (Bryant, Schewe et al. 1985) , (2) Only  5-
LOX requires accessory proteins for maximal activity: an AA -binding protein(FLAP) 
embedded in the nuclear membrane (Dixon, Diehl et al. 1990, Evans, Ferguson et al. 2008) and 
a cytosolic coactosin-like protein (Rakonjac, Fischer et al. 2006, Basavarajappa, Wan et al. 
2014) and (3) 5-LOX displays a distinctive structural variation on the canonical LOX fold. 
 In general the relative placements of the roughly 20 α-helices that make up the 
catalytic domain are conserved among LOX isoforms. 5-LOX, as well as an 11R-LOX from 
Baltic coral (Eek, Jarving et al. 2012), displays alternate placement of helix α2. This helix rims 
the U-shaped active site in other isoforms, but in 5-LOX (and 11R-LOX) the helix is “broken” 
to seal it off with insertion of aromatic amino acids into an otherwise fully accessible U-shaped 
active site. Thus the structure of Stable-5-LOX (so-called because of the presence of stabilizing 
mutations introduced distal to the active site) revealed a fully encapsulated catalytic machinery 
and neither entry into, nor positioning of substrate in the active site are obvious in the reported 
structure (Gilbert, Bartlett et al. 2011). 
We used site-directed mutagenesis, coupled with substrate and product analyses using 
High Performance Liquid Chromaography (HPLC) (as depicted in Figure 11), to sample 
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possible entry portals that may permit the substrate to gain access to the sheltered catalytic 
machinery and position itself in the active site. We also monitored the structural and functional 
integrity of the mutants generated by Thermal Shift Assay (TSA)  (Lavinder, Hari et al. 2009) 
and Enzyme Kinetics (EK)  measurements 
 
Figure 11. Schematic of HPLC analysis and sample chromatograms. HETE product profiles 
from incubations of Y181A, F177A and F1771A:Y181A mutants are shown.  
The different possible regions of substrate entry also put in to question the actual 
orientation of the substrate entry so as to generate the product of correct region- and stereo- 
specificity. In other words, whether the substrate is entering carboxyl end or the methyl end 
first also dependent on which site of the active site is the chosen entry point. To test this we 
used several substrate analogs of AA with varying levels of bulk at the carboxyl end 
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(figure12). The principle behind this approach was that if the substrate approaches via the 
carboxyl end then a bulkier group will prevent the formation of the product. Also utilization of 
such bulkier substrate will indicate a larger opening of the point of entry at the active site. 
Figure 12. Comparison of AA and substrate analogs. The natural substrate AA along with the 
several substrate analogs used for the study. The differences from AA are highlighted in red 
Our results support a model in which active site access appears to require re-
positioning, rather than a complete displacement of, Phe-177 and Tyr-181,   which penetrate 
the active site cavity. Although paring down the “cork” volume may facilitate entry into the 
active site, obstruction of “cork” entry into the active site leads to loss of enzyme specificity, 
stability, and activity.  
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2.3 Results 
We sampled, via site-directed mutagenesis,  amino acids that line the enclosed active 
site cavity of 5-LOX (Figure 13) to determine what role, if any, they might play in allowing 
AA to gain access to the catalytic iron and position itself in the active site such that 5-HpETE 
and LTA4 can be produced.  
 
Figure 13. Amino Acids in Stable-5-LOX targeted for Site-Directed Mutagenesis. The active 
site contours a rendered in blue and the amino acid side chains are shown in light blue stick 
rendering  
Mutations were made to Phe-177, Tyr-181, Ala-603, and Trp-147. The first three 
cluster to truncate one arm of what has been described as a U-shaped cavity in homologous 
enzymes with accessible catalytic sites, 15-LOX types -1 (Choi, Chon et al. 2008) and -2 
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(Kobe, Neau et al. 2014), 12-LOX (Xu, Mueser et al. 2012) and 8R-LOX (Oldham, Brash et al. 
2005, Neau, Bender et al. 2014). Phe-177 and Tyr-181 form what has been described as the 
active site “cork” (Gilbert, Bartlett et al. 2011) and the small size of the Ala at 603 appears to 
allow insertion of the “cork” into the active site.  In contrast, Trp-147 appears to block cavity 
accessibility via a sub-cavity at the base of the U (Figure 14). 
Figure 14. Stable-5-lipoxygenase has an encapsulated active site. (a) Cartoon rendering of 5-
lipoxygenase (3O8Y). There iron is shown as an orange sphere. The amino acids mutated are 
in sick rendering (C, pink, O red, N blue). (b) Close-up of the internal cavity with the mutated 
amino acids in stick rendering. 
 Each of the mutants was evaluated in terms of kinetic parameters and product profiles. 
While the in vivo product of the 5-LOX reaction is LTA4, the capacity of 5-LOX to convert the 
5-HPETE intermediate to the leukotriene is significantly compromised in vitro due to the 
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absence of FLAP. Thus, kinetic parameters derived from initial reaction rates are reported for 
HPETE formation, monitored at 238 nm as depicted in Figure 15 [The hydroperoxy products 
are rapidly reduced to the corresponding hydroxyeicosatetraenoic acids (HETEs). Products are 
expressed as ratios relative to the Prostaglandin B1 (PGB1) standard. For simplification, the 
products will henceforth be referred to as HETEs].  
 
Figure 15. Measurements of Enzyme Kinetics. (A) Schematic showing the measurement 
procedure (B) Sample Velocity vs Substrate concentration plots of Stable 5-LOX compare to 
Y181A mutant to indicate difference. 
Mutations to the “plug” cluster had dramatic effects on enzyme activity. The plug was 
trimmed by removal of either or both of the aromatic side chains (Y181A or F177A) (Figure 
16). This increased 5-HETE yields from enzyme-substrate incubations ~3- and ~1.5-fold, 
single and double mutants respectively. However, this detected increased yield came at a cost 
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to product specificity, as a small fraction of HETE other than 5-HETE was produced by 
Y181A (figure 17). The stable 5-LOX and the wild type 5-LOX do not produce any other 
HETEs under normal circumstances. 
Figure 16. A structural schematic of effects of trimming the ‘plug’ (rendered using PyMOL 
program) (A) Mutant F177A, figure scheme same as Fig. 5. Mutant amino acid is in green stick 
rendering; (B) Mutants Y181A; (C) Mutant F177AY181A, mutant amino acid shown in light 
teal. 
Figure 17. Effect of trimming the ‘plug’ on the 5-LOX activity. HETE production by different 
plug trimming mutants relative to PGB1 levels  
Neither the Y181A nor the F177A mutation appears to have an impact on enzyme 
stability, since thermal denaturation measurements revealed no significant change in Tm 
(Figure 18).  Kinetic analyses indicate that, while the Km remains essentially unchanged, the 
turnover rate for Y181A is roughly 50% enhanced with respect to Stable-5-LOX. Thus 
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“removal” of the bulky Tyr is consistent with an enhanced entry and/or egress from the active 
site. The F177A and Y181A double mutant resembles the F177A single mutant with respect to 
reaction rate as well as substrate and product specificities. Notably, though, the double mutant 
has greater thermal stability than either of the single mutant forms (Figure 18). 
 
Figure 18. Effect of trimming the ‘plug’ on the 5-LOX structural and functional integrity (A) 
Shift in Tm of the mutants as compared to stable 5-LOX, indicative of structural integrity. (B) 
Enzyme kinetic measurements comparing Km and kcat values of Stable 5-LOX with the mutants 
indicating changes in functional integrity. 
LTA4 as well as di-HETEs that may form from 5-LOX recognition of HETEs as 
substrates have absorption maxima at 270-280 nm and UV spectra that clearly differentiate 
them from HETEs.  The time frame of the kinetic measurements minimizes signal interference 
from di-HETE formation, but these off-pathway products do accumulate in the course of the 
incubations. LTA4 breakdown products and di-HETEs, both a consequence of 5-LOX activity 
with a product HETE, are grouped together as “other” in the product analyses in Table 2 and 
Figure 19.  
The presence of F177 appears to be necessary for utilization of 5-HETE as a substrate, 
as none of the mutants in which F177 was replaced with Ala produced compounds that might 
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be leukotrienes or di-HETEs, despite the fact  that the F177A mutant generates 50% more 5-
HETE than its progenitor (Figure 18) 
 Y181A and F177A mutants were able to utilize AA analogs with bulky groups at the 
carboxyl end, arachidonyl-ethanolamine (AEA) and N-arachidonyl-glycine (NAGly), to some 
extent (Table 2) 
 
Figure 19. Utilization of 5-HETE as a substrate by ‘plug’ mutants. Levels indicated as ratio of 
products detected at 270nm UV to PGB1. 
Table 2 Utilization of substrate analogs by ‘trimmed’ mutants 
Mutant 
  
  
St-5-LOX 
  
  
Y181A 
  
  
F177A 
  
  
F177A 
Y181A 
  
DGLA X X X X 
AEA X X   
NAGly X    
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We then asked whether impeding “plug” insertion by mutation of A603 might have a 
similar impact to paring down the “plug.” A large amino acid side chain at this position, as is 
found in the homologous LOXs with open cavities, should preclude cork insertion because of 
its proximity to Tyr-181 (Figure 20). 
 
Figure 20. Effect of unplugging the ‘plug’ on 5-LOX activity. HETE production by different 
plug trimming mutants relative to PGB1 levels.  
Table 3. Utilization of substrate by ‘unplugged’ mutants 
 
 
 
 
In contrast to the mutations that minimize cork volume, the A603L mutation resulted in 
significant destabilization of the protein with a 4◦ C drop in the Tm. While the Km for AA is 
native-like, the enzyme turnover is less than 10% of the parent enzyme.  Moreover, the enzyme 
has significantly impaired substrate specificity and is able to oxygenate arachidonic acid 
Mutant
   
St-5-LOX 
  
  
A603L 
   
  
A603L 
Y181A 
  
DGLA X   
AEA X   
NAGly X   
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analogs that are not substrates for the wild- type enzyme (Figure 20). Table 3 lists the behavior 
of the mutants with substrate analogs. 
 
Figure 21. Effect of unplugging the plug on the 5-LOX structural and functional integrity (A) 
Shift in Tm of the mutants as compared to stable 5-LOX,(B) Enzyme kinetic measurements. 
Remarkably, we can recover a native-like kcat (0.7 vs. 0.8 s-1) by making a 
compensatory mutation: The substitution of Y181 with Ala to whittle down the cork and allow 
insertion of Phe-177 despite the added bulk at position 603. This double mutant 
(Y181A/A603L) has enhanced thermal stability, and shows a slight decrease in Km (~2 fold) 
relative to Stable-5-LOX (Figure 21). HPLC traces of the different HETEs formed by the 
different A604 plug mutants are shown in figure 19 compared to HETE standard trace. As can 
be seen from the traces that, although the A604LY181A double mutant makes high amounts of 
5-HETE, it also makes  some amounts other different HETEs like 15-, 12/8- and even 11- , 
which is not generally seen as a product in animal LOXs. 
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Figure 22. HPLC traces of unplugged mutants. Relative HETE formation by Stable 5-LOX 
mutants A604L (Orange) and Y181AA604L (peach) compared to HETE standards (grey) 
While opening the “corked” portal seemed the more likely entrance because the open 
conformation would conform to what has been observed in other LOX structures, we also 
tested a possible access portal obstructed by W147. The substitution of Trp with the smaller 
Leu led to a significant reduction in enzyme stability.  
In addition, the enzyme has significantly reduced activity and the product specificity is 
compromised (Figure 23). These characteristics are inconsistent with Trp-147 serving as a 
functional portal. The entire data as obtained by the different ‘plug’ mutants is summarized in 
table 4 a. & b. 
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Figure 23. W147L mutant destabilizes the enzyme both structurally and functionally. (A) Shift 
in Tm of the mutants as compared to stable 5-LOX, (B) Enzyme kinetic measurements 
Table 4a. Summary of Thermal Shift and Enzyme Kinetics measurements of ‘plug’ mutants. 
Mutant 
 
 
St-5-LOX 
 
 
Y181A 
 
 
F177A 
 
 
F177A 
Y181A 
 
A603L 
 
 
A603L 
Y181A 
 
W147L 
 
 
Tm (°C) 
 
53.1±0.6 
 
52.9± 0.1 
 
51.7±0.1 
 
54.8 ±0.5 
 
49.1±0.3 
 
55.8 ±0.6 
 
49.9 ±0.1 
 
Kinetic 
parameters 
 
 
 
 
14±1.6 
 
 
 
7.6± 3.4 
 
 
 
9.8±2.1 
 
 
 
11±2 
 
 
 
9.2±3.2 
 
 
 
5.0±2.8 
 
 
 
22±7 Km(µM) 
kcat (s-1) 
 
0.8±0.03 1.2± 0.2 0.7±0.04 0.7±0.03 0.05±0.01 0.7±0.1 0.01±0.01 
 
Table 4b. Summary of product formation by ‘plug’ mutants. 
Products 
 
 
 
  4.1±0.2 
 
 
11.1±0.3 
 
 
5.8±0.3 
 
 
3.1±0.4 
 
 
0.13±0.1 
 
 
7.7±0.03 
 
 
 1.7±0.6 5-HETE 
11-HETE        nd nd nd nd nd  0.57±0.02 nd 
8/12- HETE nd 0.27±.04 nd nd 0.22±.04 1.9±.06 0.6±.05 
15-HETE nd      nd nd nd nd 0.66±.05 0.17±.01 
“other” 0.6±0.04 0.4±0.03 nd nd nd 4.1±0.5 0.25±0.1 
 
nd- Not detected 
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A second question to address was whether AA is positioned with its carboxyl 
innermost, as has been inferred from the S-stereochemistry of the product. Extrapolating from 
the structure of 8R-LOX in complex with AA (Neau, Bender et al. 2014), His-600 is deep in 
the active site where the tubular cavity dead-ends (Figure 24). 
 
Figure 24. Position of His600 in Enzyme Active Site. (A) The dotted arrow indicates the 
possible orientation of AA in the active site with the arrowhead signifying the putative position 
of the carboxyl group. (B) Position of His 600 (green sticks) with respect to the F-Y plug (blue 
sticks). 
We tested whether substitution of this charged amino acid might impact 5-LOX activity 
with two mutations: H600A and H600V. Multiple substitutions of non-polar amino acids are 
important at this position, because the depth of the active site cavity determines whether the 
pentadiene to be attacked can be positioned productively at the catalytic iron. Both 
substitutions resulted in proteins which were expressed and purified at levels comparable to 
that of the parent enzyme, and had Tms that exceed that of the parent protein. H600A displays 
severely compromised enzyme activity, in terms of both Km and turnover (Figure 25). 
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Figure 25. Effect of different His600 mutants on Thermal Shift and Enzyme Kinetic 
measurements A) Shift in Tm of the mutants as compared to stable 5-LOX, (B) Enzyme kinetic 
measurements as compared to stable 5-LOX. His600V had no detectable enzyme activity. 
The low level of activity of the mutant precluded product profile analysis by HPLC. 
The H600V mutation resulted in total lack of catalytic activity. However, we were able to rule 
out that the catalytic center is non-functional in the mutant with a “rescue” mutation that 
combined H600V with F177A:Y181A. This triple mutant produced HETEs, but not the 5- or 
15- HETE. Instead products consistent with attack at C10 were observed. Thus H600 appears 
to be essential to proper positioning of the substrate (Figure 26). The results are also 
summarized in Table 5. 
 
Figure 26. Product formation by the triple mutant as compared to stable 5-LOX. The triple 
mutant only makes 12/8 HETE as opposed to 5 HETE. 
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Table 5. Summary of the different properties of His600 mutants 
Mutant 
 
St-5-LOX 
 
H600V 
 
H600A 
 
F177A:Y181A:H
600V 
 
Tm (°C) 
 
53.1±0.1 56.4± 
0.2 
56.7± 
0.2 
54.8 (0.1) 
Kinetic 
parameters 
 
 
Km (µM) 14±1.6    nd 27±0.7      5.4±0.5 
Kcat (s-1) 0.8±0.03    nd <0.01      0.3±0.01 
Products  
5-HETE 4.1±0.2     nd     nd           nd 
8/12- HETE nd nd nd 3.4±.02 
15 HETE nd nd nd nd 
“Other” 0.6±0.04 nd nd nd 
The ability of a LOX to metabolize an AA analog which carries a bulky group at the 
carboxyl has been used as a proxy for “tail-first” entry as “head-first” entry would require that 
the additional bulk be accommodated in the active site, but with tail first entry the extra cargo 
need not enter the active site.  5-LOX does not recognize AEA or NAGly as substrates, 
consistent with head-first entry. However, several of our mutants are able to recognize these 
substrates. How might that be possible? Note in Fig 9a, 5-LOX A603 is positioned between the 
top of the U-shaped cavity of 15-LOX-2, between the two arms, with Tyr-181 simultaneously 
truncating the outermost arm and closing off the innermost arm. In 5-LOX (Fig. 9b), the deeper 
end is curved toward the entrance end such that removal of Tyr-181 might allow the ends of 
the U to join to form an egg-shaped cavity.  
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Thus it is likely that Y181A mutants tolerate extra bulk on the carboxyl end of a 
substrate analog because of the volume vacated by the Tyr.  Thus, the ability to metabolize 
AEA or NaGly is not indicative of the methyl end of the substrate situated innermost, but 
simply a consequence of a roomier cavity that allows “head-first” entry with added bulk.  
2.4 Discussion 
Lipoxygenases are characterized by two domains (Boyington, Gaffney et al. 1993, 
Gillmor, Villasenor et al. 1997, Newcomer and Brash 2015): a β-barrel domain which is 
implicated in membrane binding and a much larger α-helical domain that harbors the catalytic 
iron. Invariant histidines, as well as the main chain carboxyl of the terminal invariant Ile 
position the iron. 5-LOX displays a distinct variation of the typical LOX fold.  While the 
structures of 15-LOX-2, 15-LOX-1, 8R-LOX, and 12-LOX have revealed a solvent accessible 
active center at the base of a U-shaped cavity,  access is firmly “corked” in 5-LOX by the 
insertion of the side chains of Phe-177 and Tyr-181. Thus the path of substrate entry is not 
apparent in the crystal structure.  We asked whether 5-LOX may undergo a conformational 
change to “uncork” the active site by site-directed mutations that (1) reduce of cork volume 
and/or (2) hinder “cork” insertion.  
Active site access 
 Our data are most consistent with a model in which the cork must reposition, but it is 
not fully ejected from the binding site.  The cork is comprised of two aromatic amino acids 
(F177 and Y181), and while our data indicate that replacement of either or both with Ala 
results in catalytically active mutants, Y181A has significantly increased activity.  This 
suggests that Y181 is dispensable for the catalytic reaction, but in the native enzyme it may 
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limit access to the active site. The increase in activity, reflected by a 50% increase in kcat, is 
consistent with facilitated entry/egress to/from the active site.  
An increase in the rate of HPETE production by an R101D 5-LOX mutant was recently 
reported. This mutation disrupts a salt-link between the tightly associated membrane binding 
domain and the catalytic domain which is mediated by Asp-166 (Rakonjac Ryge, Tanabe et al. 
2014). The proximity of the corking amino acids to this domain interface is consistent with this 
observation, in the sense that disruption of the interface could allow greater flexibility in the 
corking peptide. 
While our data support repositioning of the “cork.” it also indicates that the entire cork 
cannot be displaced, as a mutation that blocks cork insertion displays less than 10% of the 
activity observed for the parent enzyme. The mutation A603L, designed to interfere with cork 
insertion due to the proximity of Tyr-181 to Ala-603, leads to a nearly total loss of activity, 
indicating that a cork amino acid side chain is necessary during the catalytic cycle. A “rescue” 
mutation, in which substitution of Y181 of the cork with Ala relieves the steric clash with the 
added bulk at position 603, renders a highly active enzyme, albeit with compromised product 
specificity. In addition, the cork amino acid F177 appears to be required for 5-LOX to process 
5-HETE, which it must do to complete the transformation of AA to LTA4. No metabolites of 5-
HETE are observed in any of the mutant forms that lack Phe-177.  
Previous mutagenesis studies aimed at reducing the volume of the active site of mouse 
and human 5-LOX have explored single site mutants at Ala-603 (Schwarz, Gerth et al. 2000, 
Schwarz, Walther et al. 2001, Hofheinz, Kakularam et al. 2013). The investigators observed 
that substitution with Ile was tolerated at this position, however for the human enzyme a 
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reduction of product isolated from cell lysates (relative to that isolated for the bacterially 
expressed wild- type enzyme) was observed. In addition, loss of regio-specificity was reported. 
In contrast, substitution with Phe at this position led to a total loss of enzyme activity. These 
results can also be interpreted the structural context we propose: that addition of bulk at 
position 603 interferes with the insertion of Phe-177/Tyr-181 in the active site and can lead to 
significantly compromised enzyme activity.   
Head first vs. tail first entry 
Further experiments suggest that His 600 is essential for positioning of the substrate, as 
mutations at this position abolish enzyme activity.  The amino acid is deepest is an elongated 
cavity that must accommodate the 20 carbon substrate. A wealth of biochemical data are 
consistent with AA entering “head” (carboxyl) first into the 5-LOX active site, while in the 
homologous 15-LOX-2 (42% sequence identity), the “tail” (hydrocarbon) enters first. This 
“head-first” vs “tail-first” relationship is a crucial determinant of product stereo-chemistry as it 
places the carbon for peroxidation proximal to the O2 channel (Schneider, Pratt et al. 2007, 
Newcomer and Brash 2015).  
One can see from Fig.10 that the 5-S and 15-S products have their peroxide groups on 
opposite sides of the product, consistent with the inverse relationship of AA positioning in the 
active site. We observed that mutation of His-600 to either a Val or an Ala resulted in an 
enzyme that can no longer generates 5-HPETE, presumably because the absence of a 
neutralizing amino acid deep in the cavity results in an enzyme that no longer favors “head-
first” substrate entry.  
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However, in a similar experiment with mouse 8-S-LOX, the substitution of the His at 
the deep end of the pocket resulted in the generation of a product consistent with tail-first entry 
(Jisaka, Kim et al. 2000). So why is a “tail-first” product, which should be a 15-HETE 
according to Fig 10, not observed for the 5-LOX H600A or H600V mutations? Cavity depth is 
an essential aspect of LOX structure as it allows the substrate to slide into the active site and 
position the pentadiene for attack. Cavity depth is clearly impacted when His is replaced by 
Ala or a Val, and one possibility that no product is observed because there is simply no 
productive alignment of a pentadiene at the catalytic center.  
Thus we combined the His600V with mutations that permit slack in the AA binding site 
by opening the “corked” end. F177A:Y181A “rescues” the H600V mutation, recovering ~50% 
of the parent enzyme activity. However, no 5-HETE is produced. Only products consistent 
with attack at carbon 10 are isolated from the incubations. Thus H600 does not play a catalytic 
role, but it is required for productive alignment of the substrate.  
Why is the active site of 5-LOX “corked”?  
Recent structures of lipoxygenases have combined to provide a robust model for 
understanding product specificity in this family(Newcomer and Brash 2015) and suggest a U-
shaped cavity with a highly conserved core of amino acids that position the appropriate 
pentadiene for attack.  
It is  not entirely  clear from the consensus model is why the active site of 5-LOX is 
“corked” since Phe-177 is a highly conserved amino acid whose counterparts in other 
arachidonate metabolizing LOX do not block access to the U-shaped channel.  Instead they 
abut the active site cavity with the plane of the aromatic ring perpendicular to the fatty acid tail 
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(Figure 27). The structures of 15-LOX-2 and 5-LOX (~42% sequence identity) superimpose 
with an r.m.s. of 1.17 Å for 576 of 674 Cα’s, but the distance between the Cα’s of Phe-177 and 
its equivalent in 5-LOX-2 (Phe-184) is ~8 Å.  
 
Figure 27. Displacement of the corking residues in 5-LOX.  5-LOX “corking” amino acids are 
displaced relative to their conserved counterparts F175, L179 (gold, lavender) in 12-LOX 
(3RDE) and rabbit 15-LOX (2P0M), respectively; F184,A188 in 15-LOX-2 (green, 4NRE) and 
Y178,R182 in 8R-LOX (white).  AA (white) and 12-LOX (orange) and 15-LOX-2 (pink) 
inhibitors are rendering in sticks.   
This major shift in side chain placement is a consequence of an unraveling of α2 in 5-
LOX so that the helical segment that contains Phe-177 and Tyr-181 is displaced in this isoform 
and these side chains can insert into the active site. Notably, substrate or inhibitors shield at 
least 50% of the accessible surface area of the Phe-177 counterparts in 8R-LOX, 12-LOX or 
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15-LOX-2, i.e they form part of the wall of the active site and even in their “open” 
conformations play critical roles in substrate recognition. In contrast the counterparts of Tyr-
181 are largely solvent accessible amino acids at the entrance to the site. However, the 8R-
LOX counterpart of Tyr-181 (Arg 182) contributes significantly to positioning of substrate in a 
productive conformation (Neau, Bender et al. 2014), presumably because it provides a counter 
charge to the substrate carboxylate. However, a charged amino acid is not conserved in other 
tail-first LOX’s with open cavity access. Thus the amino acids at the periphery of the binding 
site can vary in placement and play distinct roles in binding site definition.  
In conclusion, our results are consistent with a model in which the substrate gains 
access to the 5-LOX active site via a “cork,” which must be repositioned to allow substrate 
access. Phe-177 is likely to form an integral part of the active site, and His-600 is required to 
position the substrate for 5-HETE production.  
2.5 Materials and Methods 
Plasmid preparation 
The Stable-5-LOX construct in a pET-14b (Novagen) plasmid was used as the starting 
point for mutation (Gilbert, Bartlett et al. 2011). The various mutations were introduced by 
site-directed mutagenesis. Primers were designed to contain a given mutation and then used to 
amplify the 5-LOX plasmid using whole plasmid PCR. The resultant products were gel 
purified and re-circularized. The primers also contained unique restriction sites as silent 
mutations to verify mutation. The presence of mutations was confirmed by DNA sequencing.  
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Protein expression and Purification 
 E.coli Rosetta2 (Novagen) cells were transformed with the mutated plasmids and 
grown in small scale cultures to check for protein expression and solubility via auto-induction 
(Studier 2005). For large scale protein purification the cells were grown in Terrific Broth 
(Alpha Bioscience, MD) with 25μg/ml chloramphenicol, 100μg/ml ampicillin and 5mM 
MgSO4. The cultures were shaken at 250 rpm for 4 hours at 37°C and then the temperature was 
reduced to 25°C for an additional 25 hours to induce leaky expression. The cells were pelleted 
by centrifugation and frozen at -80°C. For protein purification, the cells were suspended in 
3ml/gm Bugbuster (Novagen) with 1μM pepstatin, 1μM leupeptin, 100μM PMSF and 2KU/gm 
DNAse I (all from Sigma). The mixture was stirred on ice for 30 min and lysed by passing 
through a French pressure cell. The lysate was centrifuged at 40000 g for 45 min.  
The resulting supernatant was loaded onto a HisTrap 5ml cobalt Sepaharose (GE 
Healthcare) column equilibrated in 50mM Tris (pH 8.0), 500mM NaCl, and 20mM imidazole 
on an AKTA FPLC system (GE Healthcare). Subsequently, the column was washed with ten 
column volumes of the above buffer and then the protein was eluted by applying a linear 
gradient of 50mM Tris-HCl (pH 8.0), 500mM NaCl and 200mM imidazole. The peak fractions 
were concentrated in an Amicon Ultra 30K (Millipore) filter to a final volume of 500 µl. 
Buffer exchange was performed twice with 15ml of 20mM Tris-HCl, pH8.0, 150mM NaCl and 
5mM TCEP-HCl. Protein was concentrated to a final concentration of 1mg/ml to 5mg/ml as 
detected by a NanoDrop spectrometer. The protein was flash frozen in liquid N2 and stored at -
80°C until usage. 
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Kinetics Assays 
The kinetic parameters for Stable-5-LOX and the different mutants were determined by 
monitoring the increase in absorbance at 238 nm in an Agilent 8453 Diode Array 
Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). The assays were performed 
with 500nM enzyme in 20 mM Tris-HCl (pH 7.5), 150 mM NaCl and 5mM TCEP. Substrate 
concentration was varied from 5 to 100 μM. Substrate concentrations (5, 10, 20, 30, 40, 50, 
100 µM) were monitored in triplicate for each sample. Km and Vmax values were determined by 
non-linear regression analysis of a plot of velocity versus substrate concentration to equation 1. 
𝑉max is the maximal velocity, 𝑆 is the substrate concentration, 𝐾m is the Michaelis constant.  
Equation 1         𝑣 =
𝑉max∙[𝑆]
𝐾m+[𝑆]
 
Product Assays 
The mutant enzymes (5μM) were incubated at 37°C with 100μM substrate or  substrate 
analog (dihomo-γ-linolenic acid (DGLA), N-arachidonyl glycine (NaGly), anandamide (AEA), 
docosahexanoic acid (DHA)  (all from Cayman Chemical Company) in 20mM Tris-HCl. (pH 
7.5), 150mM NaCl, and 5mM TCEP-HCl to a final volume of 200μl for 5min. Prostaglandin 
B1 (5μl of 50ng/μl, Cayman) was added after completion of the incubation as an internal 
standard. The products of the reaction were extracted by addition of 2μl 1N HCl and 20μl 1M 
K2HPO4 followed by 400ul dichloromethane. The mixture was vigorously shaken for 10 sec 
and centrifuged briefly to separate the phases. The organic phase was collected and washed 
twice with 400μl water, dried under a stream of N2 and stored at -20°C.  
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The products were re-suspended in 30ul of 50% Methanol and reduced by addition of 
triphenylphosphine and loaded onto a Supelco Discovery C18 Column (5μm particle size, 25 x 
0.46 cm, Sigma-Aldrich) for identification and quantitation with reversed phase HPLC with a 
diode array detector (Dionex). For quantitation, peak areas are expressed relative to that of the 
PGB1 internal standard. The mobile phase was acetonitrile/water/formic acid (60:40:0.01), and 
the flow rate 1ml/min. Four UV channels (220, 235, 270 and 280 nm) were monitored.  
Melting temperatures 
Melting temperature assays were performed as describe by Ericsson et al (22). Briefly, 
samples were prepared with 2µM enzyme in 20 mM Tris-HCl (pH 7.5), 150 mM NaCl and 
5mM TCEP and 1X SYPRO Orange stain (Invitrogen) in a final volume of 150 µL. Triplicate 
volumes of 40 µL each for every individual enzyme sample were aliquoted into a 96 well 
reaction plate. The plate was subjected to a temperature gradient of 5-94°C in 1° increments in 
a 7500 Fast Real-Time PCR system (Applied Biosystems).  
The thermal denaturation of the proteins was monitored by fluorescence of SYPRO 
Orange that occurs with protein binding (Figure28). The resulting data was exported to 
SigmaPlot (v. 9) and averaged for each triplicate. The average sigmoidal part of each curve 
was then fit into a four parameter sigmoidal equation. The Tm value was generated using the 
above.  The Tm values were measured in triplicate for each mutant. A mean of the Tm values 
with associated standard deviations (S. D) were obtained use Microsoft Excel software and  
have been reported for each mutant in Tables 4a and 5. 
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Figure 28. Thermal Shift Assay (TSA) procedure. (A)  Schematic showing the TSA procedure 
in brief (B) Sample fluorescence intensity vs temperature traces of stable 5-LOX and H600A 
mutant showing a shift in Tm, possibly due to the mutation.  
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CHAPTER 3. CONCLUSIONS 
The presence of several LOX isoforms in mammals in general and humans in particular 
is indicative of the important role this enzymes plays in smooth running of the physiological 
machinery. The widespread involvement of LOXs in various cellular functions only 
underscores the significance of this enzyme family in a living system. The spectrum of diseases 
associated with imbalance in the levels of LOXs in an organism makes them fitting drug 
targets. For successful drug designing it is imperative that every aspect of these enzymes are 
well known. A good starting point is looking at the structural and functional properties of the 
individual enzymes. 
The enzyme five lipoxygenase has been extensively studied and linked unequivocally 
to chronic and acute inflammation. The enzymatic action and the stereo specificity of 5-LOX 
depends not only on the actual orientation of the substrate AA while entering the active site, 
but also the actual positioning of one of the three chemically equivalent pentadienes present 
with respect to the catalytic Fe. However, in the current available structure indicates a lack of 
an obvious site for the substrate AA to approach the active site. And even though the catalytic 
site is somewhat similar to what is commonly seen in LOXs, the unique shape of the catalytic 
cavity also poses a potential issue regarding the proper positioning of the substrate. 
My research is an attempt to shed some light on these aspects by looking at the effect of 
site directed mutagenesis on candidate amino acid moieties in the active site. I looked at the 
effect of these single or combined amino acid mutations on both the substrate and the product 
specificity. My research indicates that an initial displacement of the so called ‘F-Y plug’ is 
required for the entry of the substrate. However for preservation of both substrate and product 
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specificities, this plug needs to be able to close back in. This is indicated by the alterations of 
both in 5-LOX mutants where the plug either rendered partially or completely unable to close.  
I also attempted to look at the possible role of the His600 moiety positioned at the blunt 
end of the active site in the enzyme activity (Figure 29). Even though the two different amino 
acid mutants had proper folding and stability as inferred from the higher than usual Tms and 
yields comparable to their active counter parts, they had very little or low activity. The effect 
of this particular mutation was somewhat alleviated by combination with F177AY181A. The 
resulting enzyme showed activity as indicated by detectable HETE products in HPLC traces. 
Nevertheless, 5-HETE was not produced by this mutant.  
 
Figure 29. Position of His 600 at Enzyme Active Site. The position of His600 is shown here 
with respect to the active site and the catalytic Fe (red sphere). The residues Phe177 and Tyr 
181 are also shown for give an idea of its overall placement.  
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These results suggest a possible role of this His in proper positioning of substrate. It 
seems that in the single His mutations the carboxyl group of AA cannot properly fit in the 
active site, thereby affecting the positioning of C7 for attack. The combination mutant, perhaps 
owing to ease of active site access, showed products that are indicative of attack on the C10. 
This might suggest that the substrate is entering methyl end first instead.  
The final piece of this puzzle would be the elucidation of how Oxygen is able to access 
the substrate.  We tried to answer this question by mutating a His residue at position 432. As 
indicated from the active site structure this His close to the catalytic Fe in position and appears 
to be a possible gate for the oxygen channel. The product assays reveal that the mutants have 
some impairment in product specificity. The H432N had comparatively lower activity and 
produced more 12/8 HETE product than 5HETE. The H432A mutant mainly produced 5HETE 
with almost similar levels of 12/8 HETE production. This mutant also had higher activity. As 
seen by the results of the product assays on the Histidine mutants (Figure 27), the role of this 
particular His in oxygen channeling remains inconclusive and open to further research. 
Figure 30. Product assays of His432 mutants. Relative HETE formation by Stable 5-LOX 
mutants H432A (Blue) and H432N (Red) compared to HETE standards(grey). 
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To conclude, my research has endeavored to explain the basis of specificity of the Human 
5-LOX and it has elucidate certain key aspects of the structural control of specificity. The 
inconclusive nature of some mutants’ indicates that further research into the enzyme activity, 
especially oxygen channeling is essential. The most helpful of these would be a crystal 
structure of the enzyme bound to the substrate. This particular goal is a definite priority for 
near future.
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